Fiche du document
2015
- doi: 10.1007/s10456-015-9462-9
- issn: 0969-6970
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s10456-015-9462-9
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/25824484
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1573-7209
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0F969B7331698
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Therapy Medications Medicaments Prescription drugs Medicines (Drugs) Pharmaceuticals Medicine (Drugs) Carcinoma Cancers Malignancy (Cancer) Malignant tumors EndotheliocytesCiter ce document
A. Weiss et al., « Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. », Serveur académique Lausannois, ID : 10.1007/s10456-015-9462-9
Métriques
Partage / Export
Résumé
Drug combinations can improve angiostatic cancer treatment efficacy and enable the reduction of side effects and drug resistance. Combining drugs is non-trivial due to the high number of possibilities. We applied a feedback system control (FSC) technique with a population-based stochastic search algorithm to navigate through the large parametric space of nine angiostatic drugs at four concentrations to identify optimal low-dose drug combinations. This implied an iterative approach of in vitro testing of endothelial cell viability and algorithm-based analysis. The optimal synergistic drug combination, containing erlotinib, BEZ-235 and RAPTA-C, was reached in a small number of iterations. Final drug combinations showed enhanced endothelial cell specificity and synergistically inhibited proliferation (p